The "Treat to Target" Approach to Rheumatoid Arthritis
Clicks: 327
ID: 114750
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
327 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #1 of 2 articles by views in rheumatic diseases clinics of north america
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Treatment of rheumatoid arthritis has evolved significantly over the past decades. Therapeutic advances have made clinical remission a feasible goal. Systematic treatment approaches taking into account objective measures of disease activity ("treat-to-target"/"T2T") have been shown to result in bett …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (41 words).
Try re-searching for a better abstract.
| Reference Key |
k2019rheumaticthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Salomon-Escoto K;Kay J;; |
| Journal | rheumatic diseases clinics of north america |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
arthritis
remission induction / methods
patient acuity
pmid:31564292
doi:10.1016/j.rdc.2019.06.001
karen salomon-escoto
jonathan kay
rheumatoid / therapy*
patient care management / methods*
patient care planning
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.